🌍·Aug 1, 2024Media
Healx Announces $47 million Series C Financing and FDA Clearance of Phase 2 IND for Neurofibromatosis Type 1 Trial
Publisher
H
Healx
Global
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Healx
- Region
- Global
- Scope
- Media
- Published
- August 1, 2024
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on healx.ai
Leave the platform to read the original full article on the publisher site.
Source: Healx
Scope: Media
Related coverage
More related coverage
American Society of Nephrology·20h ago
New nephSAP Issue: Electrolytes and Acid-Base Disorders
University of Freiburg·20h ago
EPICUR Seed Funding 2026 – submit your project ideas now
Erasmus University Rotterdam·20h ago
Tâm Ngô appointed as endowed professor of Historical Anthropology of War Legacies
University of Freiburg·20h ago